New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 29, 2013
16:35 EDTEMC, SWIR, VMW, NTGR, VLO, DHI, LLY, KERX, PFE, HES, FOn The Fly: Closing Wrap
Stocks on Wall Street were mixed as the Dow closed only 200 or so points away from a high it has not reached since October 2007. A less-than-stellar consumer confidence reading for January stalled the advance early in the session, but the averages all rebounded and closed at or near their best levels of the day, though the Nasdaq was unable to hold in positive ground... ECONOMIC EVENTS: In the U.S., the November S&P/Case-Shiller 20-city Home-Prices Index was up a seasonally adjusted 0.6% from the prior month, versus expectations for a 0.7% increase. On a year-over-year basis, the 20-city index rose 5.5%, which was nearly in-line with consensus. The Consumer Confidence reading for January fell to 58.6, versus expectations for a smaller decline to 64.0... COMPANY NEWS: Ford (F) reported quarterly results that beat expectations on both the top and bottom lines. However, concerns over Europe, where the company said it expects to lose about $2B in 2013, sent shares down 64c, or 4.64%, to $13.14... Pharma giants Pfizer (PFE) and Eli Lilly (LLY) both reported earnings that beat consensus estimates before the market opened and both rallied. Dow-member Pfizer led that index with a 3.2%, or 86c, advance to $27.70, while Lilly gained $1.68, or 3.19%, to $54.32... MAJOR MOVERS: Higher for the second straight day were shares of Hess (HES), up $5.63, or 9.01%, to $68.11 after gaining over 6% yesterday, and Keryx Biopharmaceuticals (KERX), up $2.30, or 38.01%, to $8.36 today after rising over 76% yesterday. Also higher after earnings reports were DR Horton (DHI), which gained $2.51, or 11.78%, to $23.82, and Valero (VLO), which added $4.96, or 12.78%, to $43.77. Among the noteworthy losers was VMware (VMW), down $21.18, or 21.54%, to $77.14 after its guidance disappointed the Street and the stock was downgraded by numerous firms. EMC (EMC), which holds a majority ownership stake in VMware and also reported last night, also lost $1.02, or 4.05%, to $24.18. Also lower were shares of NetGear (NTGR), down $4.45, or 10.9%, to $36.38 after agreeing to acquire Sierra Wireless's (SWIR) AirCard business assets for $138M in cash. Sierra Wireless (SWIR) advanced $1.69, or 18.45%, to $10.85 after the news... INDICES: The Dow was up 72.49, or 0.52%, to 13,954.42; the Nasdaq was down 0.64, or 0.02%, to 3,153.66; and the S&P 500 was up 7.66, or 0.51%, to 1,507.84.
News For F;PFE;LLY;HES;KERX;DHI;VLO;VMW;EMC;NTGR;SWIR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
December 9, 2014
07:37 EDTFUBS to hold a conference
Subscribe for More Information
07:11 EDTLLYEli Lilly and Incyte announce Phase 3 RA-BEACON study met primary endpoint
Subscribe for More Information
December 8, 2014
13:32 EDTPFEPfizer, Bristol-Myers announce results of human study on Eliquis
Bristol-Myers Squibb Company (BMY) and Pfizer (PFE) announced results of the first human study evaluating the reversal of the anticoagulant effect of Eliquis by 4-factor prothrombin complex concentrates in healthy subjects. The study results demonstrated that both PCCs, Sanquin’s Cofact and CSL Behring’s Beriplex P/N reversed the steady-state pharmacodynamic effects of Eliquis in several coagulation assessments, including endogenous thrombin potential. The full data will be presented today during the Antithrombotic Therapy: Anticoagulant Therapy session at the 56th annual meeting of the American Society of Hematology in San Francisco, CA. The study was an open label, randomized, placebo-controlled, three-period crossover study in 15 healthy, adult subjects. Within each period, subjects received Eliquis 10 mg twice daily. On day four, three hours after Eliquis administration, subjects received a 30-minute infusion of 4-factor PCCs, either 50 IU/kg Cofact or Beriplex P/N, or an equivalent volume of saline solution. The effect of Cofact and Beriplex P/N on the pharmacodynamics of Eliquis was based upon changes in endogenous thrombin potential, a measure of thrombin-mediated coagulation. Treatment periods were separated by an 11-day washout, after which the alternate treatment was administered. In this study, no serious adverse events, bleeding-related events or signs of thrombosis were reported with Eliquis administration with or without PCC treatment. Overall, these data demonstrate that Cofact and Beriplex P/N reversed the steady-state pharmacodynamic effects of Eliquis as measured by ETP and support further evaluation of PCCs in the management of patients treated with Eliquis who require reversal of its anticoagulant effect.
11:10 EDTFVolkswagen sees challenging developments continuing for rest of year
Volkswagen (VLKAY) said, “The challenging developments on markets worldwide – above all in Eastern Europe and South America – will continue for the remainder of this year. The Volkswagen Passenger Cars brand handled these challenges successfully during the course of the year, but was not entirely immune to their impact.” Other publicly traded companies in the passenger automotive space include Fiat Chrysler (FCAU), Ford (F), General Motors (GM), Honda (HMC), Nissan (NSANY), and Toyota (TM).
08:10 EDTLLYLilly, Anthem, HealthCore form five-year research collaboration
Eli Lilly and Company (LLY), Anthem (ANTM) and HealthCore, Inc. announced that they have formed a five-year, real-world evidence research collaboration intended to improve health outcomes for patients. The companies will jointly develop and conduct research projects in health outcomes and real-world evidence in areas of mutual interest. Each party will bring distinct and valuable contributions to the collaboration, including the U.S. provider and patient environment, research capabilities, therapeutics and methods expertise, and integrated, researchable data. The collaboration allows the organizations to explore research opportunities across disease states and incorporate surveys and other information from providers and patients.
08:07 EDTFFord management to meet with UBS
Meeting to be held in Boston on December 8 hosted by UBS.
08:03 EDTPFEPfizer announces agreement with Spark Therapeutics to develop SPK-FIX
Subscribe for More Information
December 5, 2014
10:22 EDTPFEBristol-Myers call activity attributed to takeover speculation
Subscribe for More Information
10:05 EDTPFEBristol-Myers jumps 2% amid talk of potential Pfizer bid
Shares of Bristol-Myers (BMY) are up in early trading amid chatter of a potential takeover bid from Pfizer (PFE). The stock is up $1.26 to $60.15. Bristol's market capitalization stands around $99B, less than twice that of Pfizer's $200B. A Jefferies analyst last week called Mylan (MYL) the most likely takeover target for Pfizer. Pfizer is "highly motivated" to buy a foreign company using its overseas cash and Mylan looks like the most likely target, Jefferies analyst Jeffrey Holford wrote.
10:00 EDTKERXOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Acorda Therapeutics (ACOR) initiated with a Neutral at Goldman... Builders FirstSource (BLDR) initiated with a Neutral at Sterne Agee... CSI Compressco (CCLP) initiated with a Buy at Stifel... California Resources Corp. (CRC) initiated with a Market Perform at Raymond James... Castlight Health (CSLT) initiated with an Equal Weight at First Analysis... DCP Midstream (DPM) initiated with a Buy at MLV & Co.... DSP Group (DSPG) initiated with an Outperform at Imperial Capital... Edwards Lifesciences (EW) initiated with an Outperform at Bernstein... EnLink Midstream (ENLK) initiated with a Buy at MLV & Co.... Facebook (FB) initiated with a Buy at MKM Partners... FireEye (FEYE) initiated with a Market Perform at JMP Securities... FleetCor (FLT) initiated with a Buy at Deutsche Bank... Imperva (IMPV) initiated with a Buy at Nomura... Keryx (KERX) initiated with an Outperform at Cowen... Knowles (KN) initiated with a Market Perform at FBR Capital... Marlin Midstream (FISH) initiated with a Buy at MLV & Co.... Paragon Offshore (PGN) initiated with a Sector Perform at Iberia... PepsiCo (PEP) initiated with a Buy at Evercore ISI... Proofpoint (PFPT) initiated with a Buy at Nomura... Relypsa (RLYP) initiated with an Outperform at Oppenheimer... Rocket Fuel (FUEL) initiated with a Sell at Maxim... Sprouts Farmers Markets (SFM) initiated with an Underperform at Longbow... Summit Midstream (SMLP) initiated with a Buy at MLV & Co.... TubeMogul (TUBE) initiated with a Buy at Maxim... Western Gas Partners (WES) initiated with a Buy at MLV & Co.
09:56 EDTPFERumor: Bristol-Myers strength attributed to takeover speculation
Subscribe for More Information
09:19 EDTKERXKeryx initiated with an Outperform at Cowen
Subscribe for More Information
07:51 EDTVMWSurvey indicates VMware outlook more positive than thought, says Pacific Crest
Subscribe for More Information
06:53 EDTFFord's China sales rose 2% in November, Reuters says
Subscribe for More Information
December 4, 2014
10:08 EDTVLOOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:48 EDTVLOValero initiated with a Buy at Tudor Pickering
Subscribe for More Information
08:45 EDTPFEAbbVie price target raised to $80 from $72 at Jefferies
Jefferies raised its price target for AbbVie shares to $80 while calling the company one of its top five global pharma picks for 2015. The firm's top U.S. pick is Pfizer (PFE) and its top Europe pick is Novartis (NVS). Bayer (BAYRY) and AstraZeneca (AZN) round out the top five. Jefferies thinks AbbVie's "strong momentum" will continue into the first half of 2015 and keeps a Buy rating on the name.
07:41 EDTKERXKeryx issued new U.S. patent for Auryxia
Keryx Biopharmaceuticals announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 8,901,349 on December 2. The patent, which expires in 2024, claims a method of treating hyperphosphatemia comprising administering a therapeutically effective amount of an orally administrable form of ferric citrate to a subject, wherein the orally administrable form is prepared from a ferric citrate having a BET active surface area greater than about 16 sq. m/g. The patent also claims a broad category of orally administrable forms covering Auryxia, as well as other oral formulations that could be developed in the future. On September 5, Auryxia was approved by the FDA for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis. This newly issued patent further enhances the company's key patent family, which includes U.S. Patent Nos. 7,767,851, 8,299,298, 8,338,642, 8,609,896, 8,754,257, 8,754,258, and 8,846,976 which expire in 2024, and U.S. Patent No. 8,093,423, which expires in 2026, before patent term extension. Each of these patents contains composition and method of use claims covering Auryxia.
07:17 EDTVMWFBR Capital to hold a bus tour
Subscribe for More Information
05:21 EDTVMWJuniper, VMware collaborate on cloud in APAC
Juniper Networks (JNPR) and VMware (VMW) have kick-started a joint Asia Pacific, or APAC, strategy aimed at accelerating the adoption of private cloud solutions by enterprises across APAC. The announcement builds on last year's expansion of the two companies' global technology partnership to deliver joint marketing and sales activities and interoperable products to support simple integration of the VMware NSX network virtualization platform with Juniper Networks' MetaFabric architecture for virtualized data center networking in APAC. The global market for private cloud services is forecasted to grow at a compound annual rate of 22% over the period 2013-2018 according to TechNavio. Yet the implementation and management of virtual infrastructures, together with network latency, are among the leading pain-points cited by CIOs across the APAC region. The partnership between Juniper Networks and VMware represents a shared commitment to delivering simplified, flexible solutions that enable customers to more easily realize the benefits of network virtualization and SDN as their business needs evolve.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use